Regeneron ^Investors

Regeneron Pharmaceuticals is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative medicines. They have a diverse product portfolio that includes treatments for cancer, eye diseases, and inflammatory diseases. One of their notable achievements is the development of EYLEA, an aflibercept injection, which has been successful in treating various eye conditions. Additionally, Regeneron is known for their collaboration with Sanofi in the development of a cholesterol drug that can reduce cholesterol levels by up to 72%. Founded in 1988 and headquartered in New York, USA, Regeneron Pharmaceuticals continues to make significant contributions to the field of pharmaceuticals.